Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology)

N/A

Report date: 2022/07/29 20:00:35

Base Information

Drug NameAnti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology)
Drug Alias NameMurine autologous anti-CD19 chimeric antigen receptor T cells therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Gao Boren Hospital Co LtdShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A